Director El-Dada Riad Hussein granted 350,000 KLTO shares at $0.00

Rhea-AI Filing Summary

Klotho Neurosciences, Inc. director El-Dada Riad Hussein reported receiving a grant of 350,000 shares of Common Stock on March 4, 2026. The shares were awarded under the company’s Equity Incentive Plan and were acquired at a stated price of $0.00 per share.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

El-Dada Riad Hussein

(Last) (First) (Middle)

1300 SOUTH BOULEVARD SUITE D

(Street)

CHARLOTTE NC 28203

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Klotho Neurosciences, Inc. [ KLTO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		350,000	A	(1)	350,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting person received the shares as a grant under the company's Equity Incentive Plan.

Remarks:

	Riad El-Dada	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Klotho Neurosciences (KLTO) report for El-Dada Riad Hussein?

Klotho Neurosciences reported that director El-Dada Riad Hussein received a grant of 350,000 shares of Common Stock. The award was reported as an acquisition under the company’s Equity Incentive Plan on March 4, 2026.

How many Klotho Neurosciences (KLTO) shares did El-Dada Riad Hussein acquire in this Form 4?

El-Dada Riad Hussein acquired 350,000 shares of Common Stock in this Form 4 filing. These shares were granted as an equity award under the company’s Equity Incentive Plan, increasing his directly held position to 350,000 shares following the transaction.

Was the Klotho Neurosciences (KLTO) share grant to El-Dada Riad Hussein a purchase or an award?

The transaction was an award, not a market purchase. The Form 4 classifies it as a grant, award, or other acquisition, and the footnote explains the 350,000 shares were granted under the company’s Equity Incentive Plan.

What price per share applied to El-Dada Riad Hussein’s Klotho Neurosciences (KLTO) equity grant?

The reported transaction shows a price of $0.00 per share for the 350,000 Common Stock shares. This reflects that the shares were received as a grant under the company’s Equity Incentive Plan rather than purchased on the open market.

What is El-Dada Riad Hussein’s Klotho Neurosciences (KLTO) shareholding after this Form 4 transaction?

Following the reported grant, El-Dada Riad Hussein directly holds 350,000 shares of Klotho Neurosciences Common Stock. The Form 4 indicates these shares are owned directly, with the total representing his holdings after the equity award on March 4, 2026.